PMID- 32981346
OWN - NLM
STAT- MEDLINE
DCOM- 20210125
LR  - 20210304
IS  - 1752-8984 (Electronic)
IS  - 1479-1641 (Print)
IS  - 1479-1641 (Linking)
VI  - 17
IP  - 5
DP  - 2020 May-Jun
TI  - Risk of orthostatic hypotension associated with sodium-glucose cotransporter-2 
      inhibitor treatment: A meta-analysis of randomized controlled trials.
PG  - 1479164120953625
LID - 10.1177/1479164120953625 [doi]
LID - 1479164120953625
AB  - OBJECTIVE: The aim of this study was to assess the association between 
      sodium-glucose cotransporter-2 (SGLT2) inhibitors and the risk of orthostatic 
      hypotension (OH) in patients with type 2 diabetes mellitus (T2DM). METHOD: A 
      systematic literature retrieval was performed using PubMed, Embase, and the 
      Cochrane Central Register of Controlled Trials (CENTRAL) from inception up to 16 
      October 2019. Data for study characteristics and outcomes of interest were 
      extracted from each eligible study. Pooled risk ratios (RRs) with 95% confidence 
      intervals (CI) for OH were calculated using a random-effects model. RESULT: A 
      total of 16 studies (n = 12,749) were included in our meta-analysis, with a 
      result of 44 incident OH cases (29 in the SGLT2 inhibitor group, and 15 in the 
      control group). The pooled RR was 1.17 (95% CI: 0.65-2.09). There was no evidence 
      that receiving SGLT2 inhibitors increased the risk of OH, when stratified by age, 
      duration of T2DM, or placebo-control or active-control and baseline blood 
      pressure. CONCLUSION: This meta-analysis suggested that, in general, SGLPT2 
      inhibitors did not increase the risk of OH in patients with T2DM. The possibility 
      of OH should be, therefore, considered on an individual basis, especially in 
      patients with a history of OH, long duration of T2DM, or comorbidities.
FAU - Rong, Xi
AU  - Rong X
AD  - Department of Cardiology, West China Hospital Sichuan University, Chengdu, 
      Sichuan, China.
FAU - Li, Xinran
AU  - Li X
AD  - Department of Cardiology, West China Hospital Sichuan University, Chengdu, 
      Sichuan, China.
FAU - Gou, Qiling
AU  - Gou Q
AD  - Department of Cardiology, West China Hospital Sichuan University, Chengdu, 
      Sichuan, China.
FAU - Liu, Kai
AU  - Liu K
AD  - Department of Cardiology, West China Hospital Sichuan University, Chengdu, 
      Sichuan, China.
FAU - Chen, Xiaoping
AU  - Chen X
AD  - Department of Cardiology, West China Hospital Sichuan University, Chengdu, 
      Sichuan, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - England
TA  - Diab Vasc Dis Res
JT  - Diabetes & vascular disease research
JID - 101234011
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Blood Pressure/*drug effects
MH  - Diabetes Mellitus, Type 2/diagnosis/*drug therapy
MH  - Female
MH  - Humans
MH  - Hypotension, Orthostatic/*chemically induced/diagnosis/physiopathology
MH  - Male
MH  - Middle Aged
MH  - Randomized Controlled Trials as Topic
MH  - Risk Assessment
MH  - Risk Factors
MH  - Sodium-Glucose Transporter 2 Inhibitors/*adverse effects
MH  - Treatment Outcome
PMC - PMC7919209
OTO - NOTNLM
OT  - Sodium-glucose-cotransport 2 inhibitor
OT  - adverse event
OT  - diabetes
OT  - orthostatic hypotension
COIS- Declaration of conflicting interests: The author(s) declared no potential 
      conflicts of interest with respect to the research, authorship, and/or 
      publication of this article.
EDAT- 2020/09/29 06:00
MHDA- 2021/01/26 06:00
PMCR- 2020/09/28
CRDT- 2020/09/28 05:26
PHST- 2020/09/28 05:26 [entrez]
PHST- 2020/09/29 06:00 [pubmed]
PHST- 2021/01/26 06:00 [medline]
PHST- 2020/09/28 00:00 [pmc-release]
AID - 10.1177_1479164120953625 [pii]
AID - 10.1177/1479164120953625 [doi]
PST - ppublish
SO  - Diab Vasc Dis Res. 2020 May-Jun;17(5):1479164120953625. doi: 
      10.1177/1479164120953625.